Paperbase

Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP

Frigui, Wafa Bottai, Daria Majlessi, Laleh Monot, Marc Josselin, Emmanuelle Brodin, Priscille Garnier, Thierry Gicquel, Brigitte Martin, Carlos Leclerc, Claude Cole, Stewart T. Brosch, Roland

Plos Pathogens, 2008

https://doi.org/10.1371/journal.ppat.0040033

Marc Monot

Monot Marc

ORCID: 0000-0003-0738-7335

https://research.pasteur.fr/en/member/marc-monot/

Repressor activity of the RpoS/σS-dependent RNA polymerase requires DNA binding. 10.1093/nar/gku1379

Inter- and Intraspecies Transfer of a Clostridium difficile Conjugative Transposon Conferring Resistance to MLSB 10.1089/mdr.2014.0015

Pleiotropic Role of the RNA Chaperone Protein Hfq in the Human Pathogen Clostridium difficile 10.1128/JB.01923-14

Multidisciplinary Analysis of a Nontoxigenic Clostridium difficile Strain with Stable Resistance to Metronidazole 10.1128/AAC.02350-14

The Flagellin FliC of Clostridium difficile Is Responsible for Pleiotropic Gene Regulation during In Vivo Infection 10.1371/journal.pone.0096876

Expanding the RpoS/σS-network by RNA sequencing and identification of σS-controlled small RNAs in Salmonella. 10.1371/journal.pone.0096918

COV2HTML: A Visualization and Analysis Tool of Bacterial Next Generation Sequencing (NGS) Data for Postgenomics Life Scientists 10.1089/omi.2013.0119

Sequence Similarity of Clostridium difficile Strains by Analysis of Conserved Genes and Genome Content Is Reflected by Their Ribotype Affiliation 10.1371/journal.pone.0086535

Characterization of the SigD Regulon of C. difficile and Its Positive Control of Toxin Production through the Regulation of tcdR 10.1371/journal.pone.0083748

The Spore Differentiation Pathway in the Enteric Pathogen Clostridium difficile 10.1371/journal.pgen.1003782

Genome-Wide Analysis of Cell Type-Specific Gene Transcription during Spore Formation in Clostridium difficile 10.1371/journal.pgen.1003756

Adaptive Strategies and Pathogenesis of Clostridium difficile from In Vivo Transcriptomics 10.1128/IAI.00515-13

Genome-Wide Identification of Regulatory RNAs in the Human Pathogen Clostridium difficile 10.1371/journal.pgen.1003493

Global transcriptional control by glucose and carbon regulator CcpA in Clostridium difficile 10.1093/nar/gks864

The Key Sigma Factor of Transition Phase, SigH, Controls Sporulation, Metabolism, and Virulence Factor Expression in Clostridium difficile 10.1128/JB.00272-11

Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR 10.1007/s10096-011-1224-z

Molecular Drug Susceptibility Testing and Genotyping of Mycobacterium leprae Strains from South America 10.1128/AAC.00201-11

Reannotation of the genome sequence of Clostridium difficile strain 630 10.1099/jmm.0.030452-0

Global regulation of gene expression in response to cysteine availability in Clostridium perfringens 10.1186/1471-2180-10-234

Effect of serial subculturing on the genetic composition and cytotoxic activity of Mycobacterium tuberculosis 10.1099/jmm.0.015966-0

Mycolactone Suppresses T Cell Responsiveness by Altering Both Early Signaling and Posttranslational Events 10.4049/jimmunol.0902854

Comparative genomic and phylogeographic analysis of Mycobacterium leprae 10.1038/ng.477

Are variable-number tandem repeats appropriate for genotyping Mycobacterium leprae? 10.1128/JCM.00239-08

Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

Towards an immunodiagnostic test for leprosy 10.1016/j.micinf.2006.04.002

Antigen discovery: a postgenomic approach to leprosy diagnosis 10.1128/IAI.74.1.175-182.2006

On the origin of leprosy 10.1126/science/1109759

Capsules, Toxins and AtxA as Virulence Factors of Emerging Bacillus cereus Biovar anthracis 10.1371/journal.pntd.0003455

Mycobacterium leprae genotype amplified from an archaeological case of lepromatous leprosy in Central Asia 10.1016/j.jas.2009.06.026

Integration of erm (B)-containing elements through large chromosome fragment exchange in Clostridium difficile 10.1080/2159256x.2015.1006111

Clostridium difficile: New Insights into the Evolution of the Pathogenicity Locus 10.1038/srep15023

Cpe1786/IscR of Clostridium perfringens represses expression of genes involved in Fe–S cluster biogenesis 10.1016/j.resmic.2016.03.002

Function of the CRISPR-cas system of the human pathogen: Clostridium difficile 10.1128/mBio.01112-15

Control of Clostridium difficile physiopathology in response to cysteine availability 10.1128/IAI.00121-16

Next-Generation “-omics” Approaches Reveal a Massive Alteration of Host RNA Metabolism during Bacteriophage Infection of Pseudomonas aeruginosa 10.1371/journal.pgen.1006134

Deciphering adaptation strategies of the epidemic clostridium difficile 027 strain during infection through in vivo transcriptional analysis 10.1371/journal.pone.0158204

The alternative sigma factor σ(B) plays a crucial role in adaptive strategies of Clostridium difficile during gut infection. 10.1111/1462-2920.13696

PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data 10.1038/s41598-017-07910-5

Discovery of new type I toxin–antitoxin systems adjacent to CRISPR arrays in Clostridium difficile 10.1093/nar/gky124

Comparative transcriptomics analyses reveal the conservation of an ancestral infectious strategy in two bacteriophage genera 10.1038/ismej.2017.63

What's a SNP between friends: The influence of single nucleotide polymorphisms on virulence and phenotypes of Clostridium difficile strain 630 and derivatives 10.1080/21505594.2016.1237333

High prevalence and genetic diversity of large phiCD211 (phiCDIF1296T)-like prophages in Clostridioides difficile 10.1128/AEM.02164-17

Effect of tcdR mutation on sporulation in the epidemic Clostridium difficile strain R20291 10.1128/mSphere.00383-16

Comparative genomics of Clostridium difficile 10.1007/978-3-319-72799-8_5

Clostridium difficile forms variable biofilms on abiotic surface. 10.1016/j.anaerobe.2018.05.006

Clostridium difficile Biofilm: Remodeling Metabolism and Cell Surface to Build a Sparse and Heterogeneously Aggregated Architecture. 10.3389/fmicb.2018.02084

Role of the global regulator Rex in control of NAD+ -regeneration in Clostridioides (Clostridium) difficile. 10.1111/mmi.14245

PhageTerm: a Fast and User-friendly Software to Determine Bacteriophage Termini and Packaging Mode using randomly fragmented NGS data 10.1101/108100

Identification of RNAs bound by Hfq reveals widespread RNA partners and a sporulation regulator in the human pathogen Clostridioides difficile 10.1101/2020.11.25.398065

Metabolic adaption to extracellular pyruvate triggers biofilm formation in Clostridioides difficile 10.1101/2021.01.23.427917

Identification of RNAs bound by Hfq reveals widespread RNA partners and a sporulation regulator in the human pathogen Clostridioides difficile 10.1080/15476286.2021.1882180

Metabolic adaption to extracellular pyruvate triggers biofilm formation in Clostridioides difficile 10.1038/s41396-021-01042-5

Priscille Brodin

Brodin Priscille

ORCID: 0000-0003-0991-7344

Email: priscille.brodin@inserm.fr

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364

Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535

Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009

Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297

2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163

Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650

High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016

High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114

Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b

Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648

Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779

Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u

The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573

Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675

Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a

High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0

High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044

Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583

High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645

Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507

Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062

Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064

Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006

Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006

High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06

Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009

Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0

Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049

Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0

CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859

A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x

6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322

Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b

Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681

Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2

Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831

Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029

A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125

Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025

Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086

Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18

The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129

A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627

Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360

Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316

Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902

Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13

Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18

A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J

Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516

Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127

Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277

Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224

Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Worms' Antimicrobial Peptides. 10.3390/md17090512

T(oo)bAd. 10.1038/s41589-019-0347-x

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Cell microbiology interview 10.1111/cmi.13288

Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505

Carlos Martin

Martin Carlos / RID: A-7283-2008

ORCID: 0000-0003-2993-5478

http://genmico.unizar.es/

http://www.tbvi.eu/university-of-zaragoza/

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials 10.1016/j.vaccine.2013.07.051

ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis 10.1111/cmi.12169

Global Study of IS6110 in a Successful Mycobacterium tuberculosis Strain: Clues for Deciphering Its Behavior and for Its Rapid Detection 10.1128/JCM.00970-13

Mapping IS6110 in high-copy number Mycobacterium tuberculosis strains shows specific insertion points in the Beijing genotype 10.1186/1471-2164-14-422

Recent developments in tuberculosis vaccines 10.1586/14760584.2013.856765

Attenuated Mycobacterium tuberculosis SO2 Vaccine Candidate Is Unable to Induce Cell Death 10.1371/journal.pone.0045213

Conspicuous multidrug-resistant Mycobacterium tuberculosis cluster strains do not trespass country borders in Latin America and Spain 10.1016/j.meegid.2011.06.006

Functional and Genetic Characterization of the Tap Efflux Pump in Mycobacterium bovis BCG 10.1128/AAC.05946-11

IS-seq: a novel high throughput survey of in vivo IS6110 transposition in multiple Mycobacterium tuberculosis genomes 10.1186/1471-2164-13-249

Long-term molecular surveillance of multidrug-resistant tuberculosis in Spain 10.1016/j.meegid.2011.05.016

Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4 + T-cell memory 10.1002/eji.201141903

Rapid Test for Identification of a Highly Transmissible Mycobacterium tuberculosis Beijing Strain of Sub-Saharan Origin 10.1128/JCM.06314-11

Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237 10.1016/j.tube.2010.12.007

The Transcriptional Regulatory Network of Mycobacterium tuberculosis 10.1371/journal.pone.0022178

Drug-resistant tuberculosis in the European Union: Opportunities and challenges for control 10.1016/j.tube.2010.03.008

High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100

Interactions of Attenuated Mycobacterium tuberculosis phoP Mutant with Human Macrophages 10.1371/journal.pone.0012978

Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant 10.1016/j.vaccine.2009.02.060

Multidrug-Resistant Mycobacterium tuberculosis Strain from Equatorial Guinea Detected in Spain 10.3201/eid1511.090449

MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques 10.1371/journal.pone.0005264

Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth 10.1128/AAC.00550-09

A point mutation in the two-component regulator PhoP-PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra 10.1128/JB.01465-07

Attenuated strains of Mycobacterium tuberculosis complex for laboratory and clinical use 10.1016/j.tube.2008.04.004

Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials 10.1517/14712598.8.2.201

Mapping of IS6110 insertion sites in Mycobacterium bovis isolates in relation to adaptation from the animal to human host 10.1016/j.vetmic.2007.11.038

PhoP: A Missing Piece in the Intricate Puzzle of Mycobacterium tuberculosis Virulence 10.1371/journal.pone.0003496

The Mycobacterium tuberculosis phoPR Operon Is Positively Autoregulated in the Virulent Strain H37Rv 10.1128/JB.00712-08

Transcriptional analysis of and resistance level conferred by the aminoglycoside acetyltransferase gene aac(2′)-Id from Mycobacterium smegmatis 10.1093/jac/dkm440

Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG 10.1093/jac/dkl510

Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain 10.1111/j.1365-2249.2006.03284.x

Multidrug-resistant Mycobacterium tuberculosis Beijing/W genotype in Venezuela 10.1099/jmm.0.47310-0

Recurrent tuberculosis from 1992 to 2004 in a metropolitan area 10.1183/09031936.00005107

Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum 10.1093/jac/dki436

Molecular characterisation of Mycobacterium tuberculosis isolates in the first national survey of anti-tuberculosis drug resistance from Venezuela 10.1186/1471-2180-6-90

Novel streptomycin resistance gene from Mycobacterium fortuitum 10.1128/AAC.00223-06

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs 10.1016/j.vaccine.2006.03.017

The use of mutant mycobacteria as new vaccines to prevent tuberculosis 10.1016/j.tube.2006.01.022

The virulence-associated twocomponent PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis 10.1074/jbc.C500388200

Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009

Molecular characterization of Mycobacterium tuberculosis complex isolates from wild ungulates in south-central Spain 10.1051/vetres:2004051

Revisiting the evolution of Mycobacterium bovis 10.1128/JB.187.18.6386-6395.2005

The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? 10.1183/09031936.05.00109904

IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks 10.1128/JCM.42.1.212-219.2004

Mycobacterium smegmatis displays the Mycobacterium tuberculosis virulence-related neutral red character when expressing the Rv0577 gene 10.1016/S0378-1097(04)00008-4

An essential role for phoP in Mycobacterium tuberculosis virulence 10.1046/j.1365-2958.2001.02500.x

Molecular approaches to tuberculosis 10.1046/j.1365-2958.2001.02652.x

TRANSPOSITION OF AN ANTIBIOTIC-RESISTANCE ELEMENT IN MYCOBACTERIA 10.1038/345739a0

A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity. http://dx.doi.org/10.14573/altex.1311041

A Specific Polymorphism in Mycobacterium tuberculosis H37Rv Causes Differential ESAT-6 Expression and Identifies WhiB6 as a Novel ESX-1 Component 10.1128/IAI.01824-14

Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis 10.1038/cddis.2014.313

Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator 10.1073/pnas.1406693111

Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice 10.1016/j.vaccine.2014.07.047

Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination 10.1128/CVI.00700-13

Single nucleotide polymorphism (SNP) analysis used for the phylogeny of the Mycobacterium tuberculosis complex based on a pyrosequencing assay 10.1186/1471-2180-14-21

The PhoP-Dependent ncRNA Mcr7 Modulates the TAT Secretion System in Mycobacterium tuberculosis 10.1371/journal.ppat.1004183

Neutral-red reaction is related to virulence and cell wall methyl-branched lipids in Mycobacterium tuberculosis 10.1016/j.micinf.2005.06.011

Vaccination against tuberculosis | Vacunación frente a la tuberculosis 10.1016/S1696-2818(11)70027-0

Corrigendum to "Mapping of IS6110 insertion sites in Mycobacterium bovis isolates in relation to adaptation from the animal to human host" [Vet. Microbiol. 129 (2008) 333-341] (DOI:10.1016/j.vetmic.2007.11.038) 10.1016/j.vetmic.2009.01.010

Unsuspected and extensive transmission of a drug-susceptible Mycobacterium tuberculosis strain 10.1186/1471-2466-9-3

Intracellular replication of attenuated Mycobacterium tuberculosis phoP mutant in the absence of host cell cytotoxicity 10.1016/j.micinf.2008.10.013

Epidemiology of tuberculosis on Gran Canaria: A 4 year population study using traditional and molecular approaches 10.1136/thorax.58.7.618

Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis 10.1097/00002030-199710000-00006

Use of conjugative and thermosensitive cloning vectors for transposon delivery to Mycobacterium smegmatis 10.1016/0378-1097(95)00032-Z

Onopordum nervosum as biomass source: Some aspects of its production and transformation by enzymatic hydrolysis 10.1016/0960-8524(93)90180-J

Analysis of the regions responsible for IS6110 RFLP in a single Mycobacterium tuberculosis strain 10.1016/0923-2508(92)90104-V

Factors that affect transposition mediated by the Tn21 transposase 10.1016/0147-619X(88)90007-8

Aminoglycoside-phosphotransferases APH(3′)-IV and APH(3′) synthesized by a strain of campylobacter coli 10.1093/jac/18.2.153

Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014 10.1016/j.vaccine.2015.03.056

Evolutionary Landscape of the Mycobacterium tuberculosis Complex from the Viewpoint of PhoPR: Implications for Virulence Regulation and Application to Vaccine Development 10.1128/mBio.01289-15

In Vivo IS6110 Profile Changes in a Mycobacterium tuberculosis Strain as Determined by Tracking over 14 Years 10.1128/JCM.00607-15

Klebsiella pneumoniae survives within macrophages by avoiding delivery to lysosomes 10.1111/cmi.12466

Nonspecific Beneficial Effects of BCG Vaccination in High-income Countries, Should We Extend Recommendation of BCG Vaccination? 10.1093/cid/civ148

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial 10.1016/S2213-2600(15)00435-X

MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice 10.1016/j.tube.2015.10.010

In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain 10.1016/j.tube.2016.06.005

Tuberculosis vaccines: Past, present and future 10.1002/ajh.20459

New tuberculosis vaccines 10.1016/S0213-005X(11)70019-2

Granzyme a is expressed in mouse lungs during mycobacterium tuberculosis infection but does not contribute to protection in vivo 10.1371/journal.pone.0153028

Mycobacterium tuberculosis complex genetic diversity: Mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology 10.1186/1471-2180-6-23

On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines 10.7717/peerj.1513

Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism 10.1093/infdis/jiv503

Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain 10.1128/JCM.43.3.1220-1227.2005

ESX-1-induced apoptosis during mycobacterial infection: To be or not to be, that is the question 10.3389/fcimb.2013.00088

Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis 10.1128/AAC.45.3.800-804.2001

Evaluation of the immunogenicity and diagnostic interference caused by M-tuberculosis SO2 vaccination against tuberculosis in goats 10.1016/j.rvsc.2015.09.017

Construction of a family of Mycobacterium/Escherichia coli shuttle vectors derived from pAL5000 and pACYC184: Their use for cloning an antibiotic-resistance gene from Mycobacterium fortuitum 10.1016/0378-1119(96)00202-8

Detection of a Putative TetR-Like Gene Related to Mycobacterium bovis BCG Growth in Cholesterol Using a gfp-Transposon Mutagenesis System 10.3389/fmicb.2017.00315

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries. 10.1080/14760584.2017.1324303

Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis. 10.1093/infdis/jix030

Mycobacterial diversity causing multi- and extensively drug-resistant tuberculosis in Djibouti, Horn of Africa 10.5588/ijtld.15.0268

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice. 10.3791/54440

Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines 10.1093/infdis/jiw228

Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis 10.1038/ncomms16085

Breaking Transmission with Vaccines: The Case of Tuberculosis. 10.1128/microbiolspec.MTBP-0001-2016

Evaluation of the Mycobacterium tuberculosis SO2 vaccine using a natural tuberculosis infection model in goats 10.1016/j.tvjl.2017.04.006

MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic 10.3389/fimmu.2017.01803

Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures 10.1073/pnas.1720606115

New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages 10.1371/journal.pgen.1007282

Vaccination against tuberculosis. 10.1016/j.eimc.2018.02.006

A Mycobacterium tuberculosis Beijing strain persists at high rates and extends its geographic boundaries 20 years after importation 10.1038/s41598-019-40525-6

Mycobacterium tuberculosis infection prevents asthma and abrogates eosinophilopoiesis in an experimental model 10.1111/all.13923

Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines 10.1038/s41467-019-13387-9

Update on TB Vaccine Pipeline 10.3390/app10072632

Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential 10.1016/j.ebiom.2020.102761

New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia 10.1371/journal.ppat.1008404

Independent genomic polymorphisms in the PknH serine threonine kinase locus during evolution of the Mycobacterium tuberculosis Complex affect virulence and host preference 10.1371/journal.ppat.1009061

Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment. 10.1016/j.ebiom.2020.103186

MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies. 10.1038/s41541-020-00262-8

Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. 10.1016/j.xcrm.2020.100185

Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. 10.1016/j.xcrm.2020.100187

MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG 10.1016/j.vaccine.2021.06.049

Nathalie deboosere

deboosere Nathalie

ORCID: 0000-0002-2873-5485

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227

Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619

A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114

Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007

Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013

Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011

Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002

Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10

A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018

Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013

Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007

Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015

Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3

Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030

Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5

[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650

[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163

High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14

Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040

Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u

A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648

Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675

High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023

Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645

Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583

Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07

[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062

Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05

Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006

Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004

CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Roland Brosch

Brosch Roland

ORCID: 0000-0003-2587-3863

Mycobacterium tuberculosis Meets the Cytosol: The Role of cGAS in Anti-mycobacterial Immunity. 10.1016/j.chom.2015.05.017

Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii 10.1093/gbe/evv035

Mycobacterial Pathogenomics and Evolution. 10.1128/microbiolspec.MGM2-0025-2013

Release of mycobacterial antigens 10.1111/imr.12251

Mycobacterium abscessus phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice 10.1128/IAI.02032-14

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations 10.1038/srep15443

ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection 10.1016/j.tube.2015.02.019

Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014 10.1016/j.vaccine.2015.03.056

Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650

Bovine tubercle bacilli: evolution associated with loss of transmission capacity in humans | Les bacilles de la tuberculose bovine - Une évolution aux dépens de la transmissibilité chez l'homme 10.1051/medsci/20153102003

Mycobacterium tuberculosis Exploits Asparagine to Assimilate Nitrogen and Resist Acid Stress during Infection 10.1371/journal.ppat.1003928

Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development 10.2217/fmb.14.70

Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator 10.1073/pnas.1406693111

Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy 10.1016/j.eururo.2014.02.061

A Specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies whiB6 as a novel ESX-1 component 10.1128/IAI.01824-14

A glimpse into the past and predictions for the future: The molecular evolution of the tuberculosis agent 10.1111/mmi.12720

TBCAP; Tuberculosis annotation project 10.1016/j.tube.2012.11.013

Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus 10.1111/mmi.12387

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis 10.1038/ng.2517

ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis 10.1111/cmi.12169

Characterization of Mycobacterium orygis 10.3201/eid1903.121005

The ESX-5 Associated eccB5-eccC5 Locus Is Essential for Mycobacterium tuberculosis Viability 10.1371/journal.pone.0052059

Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion-encoded PE-PPE proteins predicts vaccine potential 10.1016/j.chom.2012.03.003

Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death 10.1371/journal.ppat.1002507

Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh 10.1371/journal.pone.0040545

Molecular epidemiology of tuberculosis in rural Matlab, Bangladesh 10.5588/ijtld.11.0426

ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria 10.1111/j.1462-5822.2012.01799.x

ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells 10.4161/auto.20881

Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation 10.1111/j.1365-2958.2012.08001.x

Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies 10.3201/eid1804.110888

Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis 10.1002/eji.201141548

p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways 10.1074/jbc.M111.223610

Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants 10.1111/j.1462-5822.2010.01565.x

ESAT-6 secretion-independent impact of ESX-1 genes espF and espG 1on virulence of Mycobacterium tuberculosis 10.1093/infdis/jiq089

Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237 10.1016/j.tube.2010.12.007

Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring 10.1016/j.ejmech.2010.09.048

High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling 10.1371/journal.ppat.1001100

Entrapment of intracytosolic bacteria by septin cage-like structures 10.1016/j.chom.2010.10.009

Systematic genetic nomenclature for type VII secretion systems 10.1371/journal.ppat.1000507

Pathogenomics of mycobacteria 10.1159/000235772

Pathogenicity in the tubercle bacillus: Molecular and evolutionary determinants 10.1002/bies.200800191

Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus 10.1371/journal.pone.0005660

Myths and misconceptions: The origin and evolution of Mycobacterium tuberculosis 10.1038/nrmicro2165

Mycobacterial PE, PPE and ESX clusters: Novel insights into the secretion of these most unusual protein families 10.1111/j.1365-2958.2009.06784.x

High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors 10.1371/journal.ppat.1000645

ESX/type VII secretion systems and their role in host-pathogen interaction 10.1016/j.mib.2008.11.003

Benzothiazinones Kill Mycobacterium tuberculosis by blocking Arabinan synthesis 10.1126/science.1171583

Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis 10.1101/gr.075069.107

Functional analysis of a clonal deletion in an epidemic strain of Mycobacterium bovis reveals a role in lipid metabolism 10.1099/mic.0.2008/022269-0

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

BCG: Molecular history and new perspectives | Le BCG: Histoire moléculaire et nouvelles perspectives RMR-06-2008-25-00-01761-8425-101019-200806495

Genome plasticity of BCG and impact on vaccine efficacy 10.1073/pnas.0700869104

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/JB.00469-07

Pathogenomics: Insights into Tuberculosis and Related Mycobacterial Diseases 10.1002/352760801X.ch10

Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis 10.1093/molbev/msj120

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/IAI.74.1.88-98.2006

Contribution of mycobacterial genomics to the development of innovative strategies against tuberculosis | Apports de la génomique des mycobactéries a la définition de nouvelles stratégies thérapeutiques et vaccinales anti-tuberculeuses 10.1016/S1773-035X(06)80148-6

"A re-evaluation of M. prototuberculosis": Continuing the debate 10.1371/journal.ppat.0020095

Tuberculosis: From genome to vaccine 10.1586/14760584.4.4.541

Structure and mechanism of the alkyl hydroperoxidase AhpC, a key element of the Mycobacterium tuberculosis defense system against Oxidative Stress 10.1074/jbc.M503076200

Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: The contribution of endogenous mycolactone toxin 10.1111/j.1462-5822.2005.00546.x

Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans 10.1128/JB.187.5.1668-1676.2005

Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis 10.1371/journal.ppat.0010005

Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans 10.1073/pnas.0305877101

Genotypic Analysis of Mycobacterium tuberculosis in Bangladesh and Prevalence of the Beijing Strain 10.1128/JCM.42.2.674-682.2004

ESAT-6 proteins: Protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468

Cell Envelope Protein PPE68 Contributes to Mycobacterium tuberculosis RD1 Immunogenicity Independently of A 10-Kilodalton Culture Filtrate Protein and ESAT-6 10.1128/IAI.72.4.2170-2176.2004

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859

Is Mycobacterium africanum subtype II (Uganda I and Uganda II) a genetically well-defined subspecies of the Mycobacterium tuberculosis complex? [3] (multiple letters) 10.1128/JCM.41.3.1345-1348.2003

Royal society of tropical medicine and hygiene meeting at Manson house, London, 18 January 2001: Pathogen genomes and human health. Mycobacterial genomics 10.1016/S0035-9203(02)90222-1

Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis 10.1128/JCM.40.7.2339-2345.2002

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/IAI.70.10.5568-5578.2002

A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299

The evolution of mycobacterial pathogenicity: Clues from comparative genomics 10.1016/S0966-842X(01)02131-X

Genomics of Mycobacterium bovis 10.1054/tube.2000.0269

Tools for the population genomics of the tubercle bacilli 10.1101/gr.169200

Comparative genomics of the leprosy and tubercle bacilli 10.1016/S0923-2508(00)00117-0

Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays 10.1046/j.1365-2958.1999.01383.x

Analysis of the proteome of Mycobacterium tuberculosis in silico 10.1054/tuld.1999.0220

The high-pathogenicity island of Yersinia pseudotuberculosis can be inserted into any of the three chromosomal asn tRNA genes 10.1046/j.1365-2958.1998.01124.x

Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence 10.1038/31159

Genomic fingerprinting of 80 strains from the WHO multicenter international typing study of Listeria monocytogenes via pulsed-field gel electrophoresis (PFGE) 10.1016/S0168-1605(96)01147-6

Characterization of Listeria strains isolated from soft cheese 10.1016/0168-1605(93)90220-B

Listeriosis outbreak in France in 1992. Microbial data | Epidémie de listériose en France en 1992 aspects microbiologiques 10.1016/S0399-077X(05)81214-4

Use of pulsed field gel electrophoresis to compare large DNA-restriction fragments of Listeria monocytogenes strains belonging to serogroups 1/2 and 3 10.1016/0168-1605(91)90121-5

Subtyping of Listeria monocytogenes serovar 4b by use of low-frequency-cleavage restriction endonucleases and pulsed-field gel electrophoresis 10.1016/0923-2508(91)90080-T

Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions 10.1038/srep17078

Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis 10.1038/srep16918

Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. 10.1016/j.tube.2010.03.008

The BCG Strain Pool: Diversity Matters. 10.1038/mt.2016.18

Genome-wide mosaicism within Mycobacterium abscessus: evolutionary and epidemiological implications. 10.1186/s12864-016-2448-1

Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access. 10.1111/cmi.12622

Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria 10.1073/pnas.1604921113

Comparative Genomics and Evolution of Mycobacterium bovis BCG 10.1128/9781555817657.ch10

The Mycobacteria: a Postgenomic View 10.1128/9781555815530.ch3

Genomics ofMycobacterium Tuberculosis and Mycobacterium Leprae 10.1002/9781444311433.ch5

Genomics of the Mycobacterium tuberculosis complex and Mycobacterium leprae 10.1002/047001153x.g205204

ESX secretion systems: mycobacterial evolution to counter host immunity 10.1038/nrmicro.2016.131

Resistance to thiacetazone derivatives active against Mycobacterium abscessus involves mutations in the MmpL5 transcriptional repressor MAB_4384 10.1128/aac.02509-16

ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. 10.1111/cmi.12726

Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis 10.1038/mi.2016.140

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection 10.1016/j.celrep.2017.02.057

PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis 10.1371/journal.ppat.1006399

Predicting susceptibility to tuberculosis based on gene expression profiling in dendritic cells 10.1038/s41598-017-05878-w

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101

Evolution of virulence in the Mycobacterium tuberculosis complex 10.1016/j.mib.2017.11.021

The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis 10.3389/fmicb.2017.02284

Mutations in ppe38 block PE_PGRS secretion and increase virulence of Mycobacterium tuberculosis 10.1038/s41564-017-0090-6

Discovery of the type VII ESX-1 secretion needle? 10.1111/mmi.13579

Identification of genes required forMycobacterium abscessusgrowth in vivo with a prominent role of the ESX-4 locus 10.1073/pnas.1713195115

Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions 10.1073/pnas.1620133114

Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to Mycobacterium tuberculosis pathoadaptation 10.1371/journal.ppat.1006752

The Biology and Epidemiology of Mycobacterium canettii 10.1007/978-3-319-64371-7_2

Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs 10.2174/1381612819666131118170717

Taxonomic Diversity of Pseudomonads Revealed by Computer-interpretation of Ribotyping Data 10.1016/s0723-2020(96)80026-9

Comparative genomics of the mycobacteria 10.1016/s1438-4221(00)80083-1

Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens 10.3791/50116

Type VII Secretion Systems in Gram-Positive Bacteria 10.1007/82_2015_5015

Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name: ‘Aethiops vetus’ 10.1099/mgen.0.000063

Leprosy in red squirrels 10.1126/science.aal0145

CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection 10.1371/journal.ppat.1005770

pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence 10.1038/nmicrobiol.2015.19

A unique PE_PGRS protein inhibiting host cell cytosolic defenses and sustaining full virulence ofMycobacterium marinumin multiple hosts 10.1111/cmi.12606

The PE and PPE Protein Families of Mycobacterium tuberculosis 10.1002/9783527611614.ch7

Influence of ESAT-6 Secretion System 1 (RD1) of Mycobacterium tuberculosis on the Interaction between Mycobacteria and the Host Immune System 10.4049/jimmunol.174.6.3570

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125

ESAT-6–dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo 10.1172/jci84978

Cutting-edge science and the future of tuberculosis control 10.2471/blt.06.035386

ESAT-6 and the Mycobacterial ESX Secretion Systems 10.1128/9781555815783.ch13

RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection 10.1371/journal.ppat.1007139

Unexpected genomic and phenotypic diversity of Mycobacterium africanum Lineage 5 affects drug resistance, protein secretion and immunogenicity 10.1093/gbe/evy145

New substrates and interactors of the mycobacterial Serine/Threonine protein kinase PknG identified by a tailored interactomic approach 10.1016/j.jprot.2018.09.013

Update on the virulence factors of the obligate pathogen Mycobacterium tuberculosis and related tuberculosis-causing mycobacteria 10.1016/j.meegid.2018.12.013

Shared Pathogenomic Patterns Characterize a New Phylotype, Revealing Transition toward Host-Adaptation Long before Speciation of Mycobacterium tuberculosis 10.1093/gbe/evz162

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. 10.1021/acsnano.8b07902

Mycobacterial virulence: impact on immunogenicity and vaccine research 10.12688/f1000research.20572.1

TbD1 deletion as a driver of the evolutionary success of modern epidemic Mycobacterium tuberculosis lineages 10.1038/s41467-020-14508-5

Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis 10.1038/s41598-020-58967-8

ESX/Type VII Secretion Systems—An Important Way Out for Mycobacterial Proteins 10.1128/microbiolspec.psib-0029-2019

ESX-4, un système de sécrétion mycobactérien ancestral, essentiel pour la croissance de Mycobacterium abscessus dans les phagocytes environnementaux et humains 10.1051/medsci/2018196

Mycobacterium abscessus virulence traits unraveled by transcriptomic profiling in amoeba and macrophages 10.1371/journal.ppat.1008069

A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies 10.1126/sciadv.aaz1767

Mucosal delivery of ESX-1–expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes 10.1073/pnas.2003235117

Le BCG : histoire moléculaire et nouvelles perspectives 10.1016/s0761-8425(08)56032-3

Breaching the phagosome, the case of the tuberculosis agent 10.1111/cmi.13344

Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505

The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection 10.7554/elife.55692

IL-1R1-Dependent Signals Improve Control of Cytosolic Virulent Mycobacteria In Vivo 10.1128/mSphere.00153-21

ESX-1-Independent Horizontal Gene Transfer by Mycobacterium tuberculosis Complex Strains 10.1128/mBio.00965-21

Evolution of Mycobacterium tuberculosis : New Insights into Pathogenicity and Drug Resistance 10.1128/microbiolspec.tbtb2-0020-2016

Phthiocerol Dimycocerosates From Mycobacterium tuberculosis Increase the Membrane Activity of Bacterial Effectors and Host Receptors 10.3389/fcimb.2020.00420

Parallel in vivo experimental evolution reveals that increased stress resistance was key for the emergence of persistent tuberculosis bacilli 10.1038/s41564-021-00938-4

Wafa FRIGUI

FRIGUI Wafa

ORCID: 0000-0001-5172-7961

Mycobacterial virulence: impact on immunogenicity and vaccine research [version 1; peer review: 4 approved] 10.12688/f1000research.20572.1

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. 10.1016/j.celrep.2017.02.057

PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis. 10.1371/journal.ppat.1006399

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors. 10.1016/j.celrep.2018.03.125

pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence. 10.1038/nmicrobiol.2015.19

The changes in mycolic acid structures caused by hadC mutation have a dramatic effect on the virulence of Mycobacterium tuberculosis. 10.1111/mmi.13266

Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis. 10.1038/srep16918

CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection. 10.1371/journal.ppat.1005770

ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection. 10.1016/j.tube.2015.02.019

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083

A specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component. 10.1128/IAI.01824-14

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. 10.1038/ng.2517

Early trafficking events of Mycobacterium ulcerans within Naucoris cimicoides. 10.1111/j.1462-5822.2006.00790.x

Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. 10.1111/j.1365-2958.2012.08001.x

ESAT-6 secretion-independent impact of ESX-1 genes espF and espG1 on virulence of Mycobacterium tuberculosis. 10.1093/infdis/jiq089

Validation of the reshaped shared epitope HLA-DRB1 classification in rheumatoid arthritis. 10.1186/ar1949

Genome plasticity of BCG and impact on vaccine efficacy. 10.1073/pnas.0700869104

Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. 10.1101/gr.5942807

Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. 10.1073/pnas.0305877101

Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. 10.1128/JB.187.5.1668-1676.2005

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033

RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection 10.1371/journal.ppat.1007139

Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis 10.1038/s41598-020-58967-8